Amylx Pharmaceuticals Inc vs Capri Holdings Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Capri Holdings Ltd trades at $15.62 (market cap $1.75B). The key difference: Amylx Pharmaceuticals Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| AMLX | CPRI | |
|---|---|---|
Market Cap | $2.53B | $1.75B |
Sector | Health | Consumer Staples |
52-Week High | $24.19 | $27.66 |
52-Week Low | $7.82 | $14.98 |
Enterprise Value | $2.28B | $3.03B |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
CPRI trades at $15.295, up 2.1% today but near 52-week lows after recent analyst downgrades. The stock shows bearish technical signals with moving averages indicating selling pressure, while fundamentals reveal mixed performance - strong gross margins of 62.71% but recent net losses and declining revenue. Recent Q1 2027 earnings beat expectations despite revenue challenges, with the company revising full-year guidance downward due to Michael Kors inventory delays and softer luxury demand.
The investment case hinges on successful execution of the post-Versace turnaround strategy, with Wall Street maintaining a cautious stance (44% buy ratings) despite a $19.60 consensus target representing 28% upside. Key risks include ongoing revenue declines, luxury market volatility, and execution challenges in revitalizing the Michael Kors brand amid competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →